Excelestar Ventures led a $20m Series A round in Sealonix.

Excelestar Ventures, a venture capital firm, led a $20m Series A round in Sealonix, a company involved in development and commercialization of hemostatic sealants. "The PramStat patch builds on many years of research done by this experienced team, and now will move rapidly into clinical development. This capital will allow us to complete clinical development and pursue FDA approval. We look forward to bringing the most advanced device and method to control surgical bleeding to surgeons," Amar Sawhney, Sealonix CEO.